Figure 6.
Figure 6. Cytotoxic function generated after restimulation of the Trx80- and PSK-containing EBV-infected CBMC cultures. The EBV-infected cultures containing Trx80 or Trx80 and PSK were restimulated on the days 7 and 14 with irradiated (50 Gy) autologous EBV-infected B cells, at a ratio of 10:1, in the presence of Trx80 or Trx80 plus PSK. Beginning on day 9, 20 U/mL IL-2 was added every third day. On day 19, B lymphocytes were depleted. The remaining cells were tested for cytotoxic function. (A) Effector cells from Trx80-containing cultures. (B) Effector cells from Trx80 + PSK–containing cultures. Targets: autologous EBV-infected B cells (○), preincubated with mAb W6/32 (⬡), preincubated with mAb CR3/43 (•); autologous CD40L- and IL-4–activated B cells (□); K562 (▴); allogeneic LCLs: CBM1 (X); LS-LCL (+).

Cytotoxic function generated after restimulation of the Trx80- and PSK-containing EBV-infected CBMC cultures. The EBV-infected cultures containing Trx80 or Trx80 and PSK were restimulated on the days 7 and 14 with irradiated (50 Gy) autologous EBV-infected B cells, at a ratio of 10:1, in the presence of Trx80 or Trx80 plus PSK. Beginning on day 9, 20 U/mL IL-2 was added every third day. On day 19, B lymphocytes were depleted. The remaining cells were tested for cytotoxic function. (A) Effector cells from Trx80-containing cultures. (B) Effector cells from Trx80 + PSK–containing cultures. Targets: autologous EBV-infected B cells (○), preincubated with mAb W6/32 (⬡), preincubated with mAb CR3/43 (•); autologous CD40L- and IL-4–activated B cells (□); K562 (▴); allogeneic LCLs: CBM1 (X); LS-LCL (+).

Close Modal

or Create an Account

Close Modal
Close Modal